Swallowable Capsule for Intestinal Clotting Factor Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemophilia and other coagulation disorders require frequent intravenous injections, leading to issues such as antibody development, pain, infection risk, and limited oral delivery options due to poor absorption and degradation in the gastrointestinal tract.
Innovation Solution
A swallowable drug delivery device capable of delivering therapeutically effective doses of clotting factors, such as Factor VII, VIII, IX, and X, directly into the small intestine wall or surrounding tissue, minimizing immune response and enabling oral treatment of hemophilia and coagulation disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If clotting factors are administered via intravenous injection, then therapeutic effectiveness is achieved, but risk of infection, pain, and antibody development increases
Solution Approach 1:
The patent uses the intestinal wall as an intermediary delivery site. Instead of direct intravenous injection, clotting factors are delivered through the intestinal wall into the bloodstream, serving as a mediator that avoids needle-related harms while maintaining therapeutic effectiveness. The intestinal wall acts as a portal that bridges oral administration and systemic delivery.
Solution Approach 2:
The patent replaces the mechanical needle injection system with a swallowable capsule system. The mechanical puncture method is substituted with a chemical/biological delivery method where the capsule is ingested and releases clotting factors through the intestinal wall via diffusion or active transport mechanisms, eliminating pain and infection risk associated with needles.
2Ease of operation
If clotting factors are administered orally, then ease of administration is improved, but absorption and degradation in the gastrointestinal tract worsens
Solution Approach 1:
The patent applies local quality by targeting a specific location (intestinal wall) rather than relying on general gastrointestinal absorption. The clotting factors are delivered locally through the intestinal wall where they can directly enter the bloodstream, bypassing the harsh gastric environment and enzymatic degradation that occurs in the general GI tract.
Solution Approach 2:
The patent segments the delivery process into distinct stages: oral ingestion of capsule, release in the intestine, penetration through intestinal wall, and entry into bloodstream. This segmentation allows each stage to be optimized independently - the capsule protects the factors during transit, the intestine provides a safe release environment, and the wall penetration ensures direct systemic access.
3Reliability
If frequent intravenous injections are given, then therapeutic levels are maintained, but patient compliance and quality of life deteriorate
Solution Approach 1:
The patent replaces the repeated mechanical injection process with a single oral administration event. The swallowable capsule system substitutes multiple needle punctures with one simple ingestion act, dramatically improving patient compliance and quality of life while maintaining therapeutic effectiveness through sustained release mechanisms.
4Object-affected harmful factors
If oral delivery is attempted, then avoidance of injection harms is achieved, but drug degradation in the stomach worsens
Solution Approach 1:
The patent uses a capsule shell to protect clotting factors during their passage through the stomach. The flexible capsule structure provides a protective barrier against gastric acid and mechanical stress, allowing the factors to reach the intestine intact. The thin film capsule dissolves or opens in the intestine to release the protected factors.
Solution Approach 2:
The patent segments the gastrointestinal tract into protected (capsule interior) and exposure zones. The capsule creates a protected microenvironment that isolates the clotting factors from harmful gastric conditions, while allowing controlled interaction with the intestinal environment where absorption occurs. This spatial segmentation preserves drug stability throughout the journey.
Data Source
AI summary
Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs, e.g., Factor 8) within the GI tract. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations configured to be contained within the capsule, advanced from the capsule into the IW and/or surrounding tissue (ST) and degrade to release the TA into the bloodstream to produce a therapeutic effect (e.g., improved clotting). The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW or ST (e.g., the peritoneal cavity). Embodiments are particularly useful for delivery of CFs for treatment of clotting disorders (e.g., hemophilia) where such CFs are poorly absorbed and/or degraded within the GI tract.